Ipamorelin research

Studies this site relies on

Ordered by strength of design. Conclusions are quoted verbatim from each abstract as indexed by PubMed; read the full paper before relying on any of them.

1. Phase 2 trial Int J Colorectal Dis · 2014 PMID 25331030

   Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients

   Beck DE, Sweeney WB, McCarter MD, et al.

   Ipamorelin 0.03-mg/kg twice daily for up to 7 days was well tolerated. There were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses.

2. Primary study J Pharmacol Exp Ther · 2009 PMID 19289567

   Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus

   Venkova K, Mann W, Nelson R, et al.

   In contrast, repetitive dosing of ipamorelin (0.1 or 1 mg/kg) significantly increased the cumulative fecal pellet output, food intake, and body weight gain. The results suggest that postsurgical intravenous infusions of ipamorelin may ameliorate the symptoms in patients with POI.

3. Primary study Growth Horm IGF Res · 1999 PMID 10373343

   Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats

   Johansen PB, Nowak J, Skjaerbaek C, et al.

   The pituitary GH content was unchanged by ipamorelin treatment. Whether ipamorelin or other GH secretagogues may have a place in the treatment of children with growth retardation requires demonstration in future clinical studies.

4. Primary study Eur J Endocrinol · 1998 PMID 9849822

   Ipamorelin, the first selective growth hormone secretagogue

   Raun K, Hansen BS, Johansen NL, et al.

   In conclusion, ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH. The specificity of ipamorelin makes this compound a very interesting candidate for future clinical development.

Clinical-trial publications in PubMed

2 records carry PubMed’s clinical-trial publication type. Tagging is done by NLM indexers and occasionally includes secondary analyses.

Newest records

The most recent PubMed additions for this query at the data-edition date, regardless of design.

• Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review Sex Med Rev · 2026 · Review
• Peptide Supplements and Their Therapeutic Applications in Sports Medicine Am J Sports Med · 2026 · Primary study
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance Sports Med · 2026 · Review
• A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review J Sports Med Phys Fitness · 2026 · Review
• The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration Front Endocrinol (Lausanne) · 2026 · Review
• Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications JBJS Rev · 2026 · Review
• Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives Int J Mol Sci · 2026 · Review
• Therapeutic peptides in gerontology: mechanisms and applications for healthy aging Front Aging · 2026 · Review
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions J Am Acad Orthop Surg Glob Res Rev · 2026 · Review
• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians Am J Sports Med · 2026 · Review